# A Study of EMB-02 in Participants With Advanced Solid Tumors

> **NCT04618393** · PHASE1,PHASE2 · TERMINATED · sponsor: **Shanghai EpimAb Biotherapeutics Co., Ltd.** · enrollment: 47 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** EMB-02

## Key facts

- **NCT ID:** NCT04618393
- **Lead sponsor:** Shanghai EpimAb Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-11
- **Primary completion:** 2023-07-12
- **Final completion:** 2024-03-21
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Company's resource optimization and product's development change
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04618393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04618393, "A Study of EMB-02 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04618393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*